Research graph
References from suPAR Identifies Treatment-Resistant Inflammatory Risk Beyond hs-CRP in Type 2 Diabetes With Coronary Artery Disease: An Ancillary Analysis of BARI 2D. Local targets link to admitted publications; unresolved targets remain external evidence.
Coronary artery disease and diabetes mellitus
2014 · External reference
Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes
10.1186/s12933-021-01409-0 · 2021 · External reference
Antiinflammatory therapy with canakinumab for atherosclerotic disease
10.1056/nejmoa1707914 · 2017 · External reference
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
10.1056/nejmoa0807646 · 2008 · External reference
Colchicine in acute myocardial infarction
10.1056/nejmoa2405922 · 2025 · External reference
Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study
10.2337/db12-1625 · 2014 · External reference
Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four U.K. prospective cohort studies
10.2337/dc11-1588 · 2012 · External reference
Role of soluble urokinase-type plasminogen activator receptor in cardiovascular disease
10.1007/s11886-023-01991-7 · 2023 · External reference
Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis
10.1172/jci158788 · 2022 · External reference
Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease
10.1038/nm.4242 · 2017 · External reference
Predicting mortality in African Americans with type 2 diabetes mellitus: soluble urokinase plasminogen activator receptor, coronary artery calcium, and high-sensitivity C-reactive protein
10.1161/jaha.117.008194 · 2018 · External reference
Soluble urokinase plasminogen activator receptor (suPAR) mediates the impact of diabetes on adverse outcomes in coronary artery disease
10.2337/dc25-0940 · 2026 · External reference
Soluble urokinase receptor and acute kidney injury
10.1056/nejmoa1911481 · 2020 · External reference
Soluble urokinase receptor and chronic kidney disease
10.1056/nejmoa1506362 · 2015 · External reference
The D2D3 form of uPAR acts as an immunotoxin and may cause diabetes and kidney disease
10.1126/scitranslmed.abq6492 · 2023 · External reference
RAGE and αVβ3-integrin are essential for suPAR signaling in podocytes
10.1016/j.bbadis.2021.166186 · 2021 · External reference
Soluble urokinase plasminogen activator receptor and outcomes in HFpEF: a TOPCAT ancillary study
10.1002/ehf2.15423 · 2025 · External reference
Overall and inter-individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes
10.1111/dom.15209 · 2023 · External reference
A randomized trial of therapies for type 2 diabetes and coronary artery disease
10.1056/nejmoa0805796 · 2009 · External reference
Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individuals
10.1016/j.clinbiochem.2019.05.010 · 2019 · External reference
New creatinine- and cystatin C-based equations to estimate GFR without race
10.1056/nejmoa2102953 · 2021 · External reference
Sotagliflozin, suPAR, and cardiovascular outcomes in patients with diabetes and heart failure: a SOLOIST-WHF ancillary study
10.1016/j.cardfail.2026.01.018 · 2026 · External reference
Effect of simvastatin and ezetimibe on suPAR levels and outcomes
10.1016/j.atherosclerosis.2018.03.030 · 2018 · External reference
Inflammatory markers and measures of cardiovascular autonomic neuropathy in type 1 diabetes
10.1161/jaha.124.036787 · 2025 · External reference
Unexplained residual risk in type 2 diabetes: how big is the problem?
10.1007/s11886-024-02055-0 · 2024 · External reference
Statins for the “SMuRFLess But Inflamed”: silent vascular inflammation and the challenge of translational science
10.1016/j.jacbts.2025.101318 · 2025 · External reference
Soluble urokinase plasminogen activator receptor (suPAR) as a biomarker of systemic chronic inflammation
10.3389/fimmu.2021.780641 · 2021 · External reference
suPAR: the molecular crystal ball
10.1155/2009/504294 · 2009 · External reference
The role of suPAR and related proteins in kidney, heart diseases, and diabetes
10.1172/jci197141 · 2026 · External reference
Healthy lifestyles reduce suPAR and mortality in a Danish general population study
10.1186/s12979-018-0141-8 · 2019 · External reference
